JNJ
NYSE
Johnson & Johnson
$5.14
Dividend per share FY2025
Quarterly
Frequency
1.59x
FCF cover FY2025
3-yr avg 1.61x
5.2%
Dividend growth, 5-yr CAGR
Dividend per share · FY2025$5.14as reported in the 10-K
Latest quarterly dividend$1.34quarter ended 2026-09-27 · filing
Dividend growth · 5 years5.2%compound annual rate
FCF cover · FY20251.59x3-year average 1.61x
Consecutive increases4years, within FY2021–FY2025
JNJ dividend record
Annual figures as reported in Johnson & Johnson’s Form 10-K filings with the US SEC. Free cash flow = operating cash flow − capital expenditure. FCF cover = free cash flow ÷ dividends paid. Each row links to its filing. Data as of SEC EDGAR, retrieved 14 Nov 2026.
| Fiscal year | Year end | Dividend / share | Change | Dividends paid | Free cash flow | FCF cover | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 2025-12 | $5.14 | +4.7% | $12.38bn | $19.70bn | 1.59x | 10-K data |
| FY2024 | 2024-12 | $4.91 | +4.5% | $11.82bn | $19.84bn | 1.68x | 10-K data |
| FY2023 | 2023-12 | $4.70 | +5.6% | $11.77bn | $18.25bn | 1.55x | 10-K data |
| FY2022 | 2023-01 | $4.45 | +6.2% | $11.68bn | $17.18bn | 1.47x | 10-K data |
| FY2021 | 2022-01 | $4.19 | +5.3% | $11.03bn | $19.76bn | 1.79x | 10-K data |
| FY2020 | 2021-01 | $3.98 | +6.1% | $10.48bn | $20.19bn | 1.93x | 10-K data |
| FY2019 | 2019-12 | $3.75 | +5.9% | $9.92bn | $19.92bn | 2.01x | 10-K data |
| FY2018 | 2018-12 | $3.54 | +6.6% | $9.49bn | $18.53bn | 1.95x | 10-K data |
| FY2017 | 2017-12 | $3.32 | +5.4% | $8.94bn | $17.78bn | 1.99x | 10-K data |
| FY2016 | 2017-01 | $3.15 | — | $8.62bn | $15.54bn | 1.80x | 10-K data |
- Dividend per share rose every year in the 10-year window shown (FY2016–FY2025). Records before FY2016 are not yet verified on DIVpedia, so we do not state a longer streak.
- Johnson & Johnson uses a 52/53-week fiscal year, so some fiscal years end in early January of the following calendar year. We label each year by the calendar year it mostly covers.
- Dividend per share here is the amount paid in each fiscal year, as the company reports it.
Original source: Johnson & Johnson filings on SEC EDGAR · How we calculate · Report an error
General information only — not financial advice. Share prices and dividend yields are not shown until a licensed price feed is connected.
About Johnson & Johnson
Johnson & Johnson develops prescription medicines and medical devices. It separated its consumer-health business into Kenvue in 2023.
Common Stock
1.5-2x
Quarterly
